| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| IMTXImmatics N.V. | 1.33B | 9.92 | 70.86 | 188.6% | -136.72% | -27.81% | 0.03 | |
| CTMXCytomX Therapeutics, Inc. | 720.1M | 4.25 | 11.18 | 36.45% | 24.66% | 26.09% | ||
| IOVAIovance Biotherapeutics, Inc. | 881.27M | 2.22 | -1.73 | 136.99% | -158.78% | -56.62% | 0.08 | |
| REPLReplimune Group, Inc. | 572.64M | 7.30 | -2.38 | -117.82% | 0.18 | |||
| NKTRNektar Therapeutics | 719.28M | 35.36 | -4.07 | 9.22% | -192.87% | -141.9% | 1.69 | |
| IMNMImmunome, Inc. | 2.52B | 22.85 | -4.57 | -35.5% | -23.01% | -84.4% | 0.03 | |
| IBRXImmunityBio, Inc. | 3.89B | 3.95 | -6.37 | 22.71% | -422.28% | |||
| NRIXNurix Therapeutics, Inc. | 1.91B | 18.86 | -6.55 | -29.15% | -292.5% | -65.76% | 0.05 |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 73K | 3.34M |
| Revenue Growth % | - | - | - | - | - | - | 44.81% |
| Cost of Goods Sold | 73.93K | 80.98K | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - |
| Gross Profit | -73.93K | -80.98K | 0 | 0 | 0 | 73K | 3.34M |
| Gross Margin % | - | - | - | - | - | 1% | 1% |
| Gross Profit Growth % | - | -0.1% | 1% | - | - | - | 44.81% |
| Operating Expenses | 5.63M | 11.28M | 16.57M | 25.83M | 25.26M | 22.27M | 18.08M |
| OpEx % of Revenue | - | - | - | - | - | 305.07% | 5.41% |
| Selling, General & Admin | 1.88M | 2.63M | 5.67M | 6.18M | 8.06M | 10.08M | 7.32M |
| SG&A % of Revenue | - | - | - | - | - | 138.07% | 2.19% |
| Research & Development | 3.73M | 8.65M | 11.7M | 19.58M | 17.06M | 11.92M | 10.46M |
| R&D % of Revenue | - | - | - | - | - | 163.23% | 3.13% |
| Other Operating Expenses | 15K | 0 | -800K | 71K | 144K | 275K | 302K |
| Operating Income | -5.63M | -11.36M | -16.57M | -25.83M | -25.26M | -22.2M | -14.73M |
| Operating Margin % | - | - | - | - | - | -304.07% | -4.41% |
| Operating Income Growth % | - | -1.02% | -0.46% | -0.56% | 0.02% | 0.12% | 0.34% |
| EBITDA | -5.55M | -11.28M | -16.46M | -25.49M | -24.69M | -21.58M | -14.13M |
| EBITDA Margin % | - | - | - | - | - | -295.64% | -4.22% |
| EBITDA Growth % | - | -1.03% | -0.46% | -0.55% | 0.03% | 0.13% | 0.35% |
| D&A (Non-Cash Add-back) | 73.93K | 80.98K | 105K | 344K | 571K | 615K | 607K |
| EBIT | -6.25M | -11.98M | -16.57M | -24.55M | -23.14M | -22.02M | -10.39M |
| Net Interest Income | -696K | -1.21M | -7K | 1.12M | 1.32M | -743K | -708K |
| Interest Income | 2K | 9K | 216K | 2.04M | 2.83M | 154K | 254K |
| Interest Expense | 698K | 1.22M | 223K | 915K | 1.51M | 897K | 962K |
| Other Income/Expense | -636.93K | -656.87K | -7K | 1.12M | 1.32M | -718K | 3.38M |
| Pretax Income | -6.27M | -12.02M | -16.57M | -24.71M | -23.94M | -22.91M | -11.36M |
| Pretax Margin % | - | - | - | - | - | -313.9% | -3.4% |
| Income Tax | -735K | -824.84K | -1.56M | -178K | -772K | -790K | -788K |
| Effective Tax Rate % | 0.88% | 0.93% | 0.91% | 0.99% | 0.97% | 0.97% | 0.93% |
| Net Income | -5.54M | -11.19M | -15.02M | -24.53M | -23.17M | -22.13M | -10.57M |
| Net Margin % | - | - | - | - | - | -303.08% | -3.16% |
| Net Income Growth % | - | -1.02% | -0.34% | -0.63% | 0.06% | 0.05% | 0.52% |
| Net Income (Continuing) | -5.53M | -11.19M | -15.02M | -24.53M | -23.17M | -22.13M | -10.57M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -11.52 | -27.60 | -37.00 | -50.40 | -39.20 | -32.40 | -9.80 |
| EPS Growth % | - | -1.4% | -0.34% | -0.36% | 0.22% | 0.17% | 0.7% |
| EPS (Basic) | -11.52 | -27.60 | -37.00 | -50.40 | -39.20 | -32.40 | -9.80 |
| Diluted Shares Outstanding | 479.97K | 404.97K | 404.97K | 487.33K | 590.97K | 683.39K | 1.07M |
| Basic Shares Outstanding | 479.97K | 404.97K | 404.97K | 487.33K | 590.97K | 683.39K | 1.07M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 8.38M | 10.96M | 10.95M | 34.7M | 16.98M | 8.35M | 8.77M |
| Cash & Short-Term Investments | 7.43M | 9.56M | 5.83M | 32.17M | 13.18M | 5.58M | 5.05M |
| Cash Only | 7.43M | 9.56M | 5.83M | 32.17M | 13.18M | 5.58M | 5.05M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 772K | 0 | 0 | 0 | 0 | 0 | 1.86M |
| Days Sales Outstanding | - | - | - | - | - | - | 202.8 |
| Inventory | -1.36M | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 931K | 3.94M | 1.9M | 1.31M | 1.07M | 900K |
| Total Non-Current Assets | 130K | 126K | 1.01M | 5.46M | 5.04M | 4.54M | 3.72M |
| Property, Plant & Equipment | 130K | 101K | 221K | 5.17M | 4.67M | 4.34M | 3.51M |
| Fixed Asset Turnover | - | - | - | - | - | 0.02x | 0.95x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 100K | 93K | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 44K |
| Other Non-Current Assets | 0 | 25K | 694K | 191K | 365K | 196K | 162K |
| Total Assets | 8.51M | 11.08M | 11.96M | 40.16M | 22.02M | 12.89M | 12.48M |
| Asset Turnover | - | - | - | - | - | 0.01x | 0.27x |
| Asset Growth % | - | 0.3% | 0.08% | 2.36% | -0.45% | -0.41% | -0.03% |
| Total Current Liabilities | 9.42M | 1.72M | 4.93M | 4.32M | 3.76M | 7.08M | 4.37M |
| Accounts Payable | 139K | 646K | 3.67M | 2.85M | 2.08M | 2.69M | 2.97M |
| Days Payables Outstanding | 686.28 | 2.91K | - | - | - | - | - |
| Short-Term Debt | 8.57M | 0 | 0 | 126K | 136K | 159K | 159K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 440K | 177K | 180K | 46K | 885K | 3.02M | 927K |
| Current Ratio | 0.89x | 6.36x | 2.22x | 8.03x | 4.51x | 1.18x | 2.01x |
| Quick Ratio | 1.03x | 6.36x | 2.22x | 8.03x | 4.51x | 1.18x | 2.01x |
| Cash Conversion Cycle | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 24K | 0 | 0 | 3.4M | 9.96M | 10.53M | 9.77M |
| Long-Term Debt | 0 | 0 | 0 | 1.04M | 7.86M | 8.49M | 8.01M |
| Capital Lease Obligations | 24K | 0 | 0 | 2.21M | 1.95M | 1.9M | 1.62M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 153K | 144K | 149K | 141K |
| Total Liabilities | 9.44M | 1.72M | 4.93M | 7.73M | 13.72M | 17.62M | 14.14M |
| Total Debt | 8.67M | 36K | 20K | 3.69M | 10.26M | 10.87M | 10.1M |
| Net Debt | 1.24M | -9.52M | -5.81M | -28.48M | -2.93M | 5.29M | 5.05M |
| Debt / Equity | - | 0.00x | 0.00x | 0.11x | 1.24x | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - |
| Interest Coverage | -8.06x | -9.30x | -74.30x | -28.23x | -16.75x | -24.75x | -15.31x |
| Total Equity | -931K | 9.36M | 7.04M | 32.44M | 8.3M | -4.73M | -1.65M |
| Equity Growth % | - | 11.06% | -0.25% | 3.61% | -0.74% | -1.57% | 0.65% |
| Book Value per Share | -1.94 | 23.12 | 17.38 | 66.56 | 14.05 | -6.92 | -1.54 |
| Total Shareholders' Equity | -931K | 9.36M | 7.04M | 32.44M | 8.3M | -4.73M | -1.65M |
| Common Stock | 2.11M | 2.48M | 2.65M | 3.75M | 3.89M | 5.9M | 10.52M |
| Retained Earnings | -6.98M | -15.81M | -27.28M | -50.43M | -85.84M | -107.97M | -118.54M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 3.94M | -169K | 226K | -1.32M | 9.53M | 9.89M | -3.6M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -1.99M | -7.02M | -12.44M | -21.93M | -25.77M | -17.69M | -12.94M |
| Operating CF Margin % | - | - | - | - | - | -242.34% | -3.87% |
| Operating CF Growth % | - | -2.53% | -0.77% | -0.76% | -0.18% | 0.31% | 0.27% |
| Net Income | -5.54M | -11.2M | -15.02M | -24.53M | -23.17M | -22.13M | -10.57M |
| Depreciation & Amortization | 74K | 81K | 105K | 344K | 571K | 615K | 607K |
| Stock-Based Compensation | 2.07M | 2.36M | 3.41M | 1.38M | 942K | 479K | 357K |
| Deferred Taxes | -735K | -825K | -2.07M | -190K | -998K | -984K | -813K |
| Other Non-Cash Items | 1.16M | 1.99M | 919K | -171K | -243K | 2.76M | -3.04M |
| Working Capital Changes | 981K | 573K | 215K | 1.24M | -2.88M | 1.56M | 520K |
| Change in Receivables | 443K | -337K | -2.5M | 1.86M | -1.49M | 1.11M | 374K |
| Change in Inventory | 446K | 0 | 0 | 0 | 1.49M | 0 | 0 |
| Change in Payables | 79K | 507K | 1.8M | -647K | -599K | 502K | 449K |
| Cash from Investing | 6K | -68K | -393K | -1.33M | -268K | -93K | -3K |
| Capital Expenditures | -7K | -68K | -358K | -1.3M | -292K | -87.13K | 0 |
| CapEx % of Revenue | - | - | - | - | - | 1.19% | - |
| Acquisitions | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 13K | 0 | -35K | -60K | -13 | 133 | 0 |
| Cash from Financing | 9.03M | 9.51M | 8.82M | 49.8M | 7.85M | 10.69M | 13.13M |
| Debt Issued (Net) | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - |
| Other Financing | 0 | -13K | -128K | -3.76M | 0 | 2.15M | -2.29M |
| Net Change in Cash | - | - | - | - | - | - | - |
| Free Cash Flow | -2M | -7.09M | -12.83M | -23.29M | -26.07M | -17.78M | -12.94M |
| FCF Margin % | - | - | - | - | - | -243.53% | -3.87% |
| FCF Growth % | - | -2.55% | -0.81% | -0.82% | -0.12% | 0.32% | 0.27% |
| FCF per Share | -4.16 | -17.50 | -31.68 | -47.80 | -44.11 | -26.01 | -12.06 |
| FCF Conversion (FCF/Net Income) | 0.36x | 0.63x | 0.83x | 0.89x | 1.11x | 0.80x | 1.22x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -265.52% | -183.15% | -124.29% | -113.74% | -1238.11% | - |
| Return on Invested Capital (ROIC) | -1388.24% | -11916.88% | -2337.91% | -747.37% | -405.96% | -561.29% | -558.74% |
| Gross Margin | - | - | - | - | - | 100% | 100% |
| Net Margin | - | - | - | - | - | -30308.22% | -316% |
| Debt / Equity | - | 0.00x | 0.00x | 0.11x | 1.24x | - | - |
| Interest Coverage | -8.06x | -9.30x | -74.30x | -28.23x | -16.75x | -24.75x | -15.31x |
| FCF Conversion | 0.36x | 0.63x | 0.83x | 0.89x | 1.11x | 0.80x | 1.22x |
| Revenue Growth | - | - | - | - | - | - | 4480.82% |
Evaxion Biotech A/S (EVAX) reported $7.7M in revenue for fiscal year 2024.
Evaxion Biotech A/S (EVAX) grew revenue by 4480.8% over the past year. This is strong growth.
Evaxion Biotech A/S (EVAX) reported a net loss of $5.4M for fiscal year 2024.
Evaxion Biotech A/S (EVAX) had negative free cash flow of $12.9M in fiscal year 2024, likely due to heavy capital investments.